$712 Million is the total value of TANG CAPITAL MANAGEMENT LLC's 25 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 325.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LJPC | Buy | LA JOLLA PHARMACEUTICAL CO | $33,937,000 | +74.8% | 8,080,345 | +63.6% | 4.76% | +105.5% |
| ANAB | Buy | ANAPTYSBIO INC | $32,369,000 | +8.0% | 2,290,827 | +24.2% | 4.54% | +27.0% |
| BIO | New | BIO RAD LABS INCcl a | $28,045,000 | – | 80,000 | +100.0% | 3.94% | – |
| UTHR | New | UNITED THERAPEUTICS CORP DEL | $19,763,000 | – | 208,415 | +100.0% | 2.78% | – |
| EOLS | Buy | EVOLUS INC | $13,674,000 | -57.4% | 3,295,000 | +25.0% | 1.92% | -49.9% |
| SGMO | New | SANGAMO THERAPEUTICS INC | $12,950,000 | – | 2,032,980 | +100.0% | 1.82% | – |
| EGRX | New | EAGLE PHARMACEUTICALS INC | $11,758,000 | – | 255,616 | +100.0% | 1.65% | – |
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $6,752,000 | +120.9% | 800,000 | +129.0% | 0.95% | +159.7% |
| CHRS | New | COHERUS BIOSCIENCES INC | $5,677,000 | – | 350,000 | +100.0% | 0.80% | – |
| LSACU | New | LIFESCI ACQUISITION CORPunit 03/31/2025 | $4,999,000 | – | 500,000 | +100.0% | 0.70% | – |
| RDUS | New | RADIUS HEALTH INC | $3,900,000 | – | 300,000 | +100.0% | 0.55% | – |
| VNDA | New | VANDA PHARMACEUTICALS INC | $3,106,000 | – | 299,800 | +100.0% | 0.44% | – |
| CTMX | New | CYTOMX THERAPEUTICS INC | $2,301,000 | – | 300,000 | +100.0% | 0.32% | – |
| ENTA | New | ENANTA PHARMACEUTICALS INC | $693,000 | – | 13,483 | +100.0% | 0.10% | – |
| ITCI | New | INTRA CELLULAR THERAPIES INC | $637,000 | – | 41,444 | +100.0% | 0.09% | – |
| CMRX | New | CHIMERIX INC | $621,000 | – | 431,273 | +100.0% | 0.09% | – |
| UPS | New | UNITED PARCEL SERVICE INCcl b | $93,000 | – | 1,000 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HERON THERAPEUTICS INC | 37 | Q3 2023 | 55.0% |
| LA JOLLA PHARMACEUTICAL CO | 34 | Q2 2022 | 37.1% |
| ROCKET PHARMACEUTICALS INC | 20 | Q3 2023 | 31.6% |
| BIOMARIN PHARMACEUTICAL INC | 18 | Q3 2017 | 12.1% |
| ODONATE THERAPEUTICS INC | 17 | Q4 2021 | 69.8% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 18.4% |
| COHERUS BIOSCIENCES INC | 15 | Q3 2023 | 2.7% |
| EQUILLIUM INC | 13 | Q3 2023 | 1.2% |
| RELMADA THERAPEUTICS INC | 12 | Q4 2022 | 6.2% |
| MIRATI THERAPEUTICS INC | 11 | Q3 2023 | 10.9% |
View TANG CAPITAL MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 4 | 2024-02-02 |
| 4 | 2023-12-18 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-10-13 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-06-01 |
| 4 | 2023-06-01 |
| 4 | 2023-05-30 |
View TANG CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.